Clinical trials: Healthy Male/Female Subjects
Cystic Fibrosis
A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects
This is a first in human study of ETD001 a new drug being developed for the treatment of cystic fibrosis. The study is a randomised, placebo-controlled, double-blind interventional study to assess the safety, tolerability and…
- Trial name
- NCT04926701
- Testing
- ETD001 single dose, ETD001 multiple twice daily doses, ETD001 multiple once daily doses
- Where
- United Kingdom
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Enterprise Therapeutics Ltd
Pharmacokinetics, Healthy Subjects
Pharmacokinetics Trial of Isosorbide Mononitrate 0.5% Gel for Intra Anal Application in Healthy Subjects
This is a Phase I trial to evaluate pharmacokinetics and safety of Isosorbide Mononitrate gel for intra anal administration in healthy subjects.
- Trial name
- NCT04729088
- Testing
- Isosorbide mononitrate
- Volunteers
- healthy volunteers welcome
- Sponsor
- Biolab Sanus Farmaceutica
Alzheimer's Disease
Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163
The primary objective is to assess the safety and tolerability of a single oral dose of BMS-708163 in healthy young male subjects and in elderly male and female subjects.
- Trial name
- NCT01454115
- Testing
- BMS-708163 (Gamma-Secretase Inhibitor)
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Pulmonary Disease, Chronic Obstructive
A Study to Assess the Effects of Repeat Doses of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Severe Impairment.
This study will assess the saftey of giving fluticasone furoate 200mcg/GW642444M 25mcg once daily for 7 days to patients with severe renal imparement.
- Trial name
- NCT01266980
- Testing
- Inhaled FF/ GW642444M (200/25mcg)
- Where
- Czechia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Relative Bioavailability of Telmisartan and HCTZ in Two Experimental Formulations Compared to the Standard Formulation Telmisartan and HCTZ in Healthy Female and Male Subjects
Study to assess the comparative pharmacokinetics of telmisartan/HCTZ in two new formulations based on sodium salt compared to the present commercial formulation (MicardisPlus®)
- Trial name
- NCT02262572
- Testing
- Telmisartan /HCTZ - compression tablet (DC), Telmisartan /HCTZ - dry granulation tablet (DG), Telmisartan /HCTZ - present commercial formulation
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Electrophysiological Effects of Tipranavir Co-administered With Ritonavir on the QT Interval in Healthy Female and Male Subjects
To demonstrate that tipranavir (TPV) co-administered with ritonavir (RTV) does not affect the QT interval more than placebo co-administered with ritonavir
- Trial name
- NCT02248883
- Testing
- TPV low, Moxifloxacin, TPV high
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Cefadroxil 500 mg Capsules Under Fasting Conditions
The objective of this study is to compare the relative bioavailability of cefadroxil 500 mg capsules (manufactured by Teva Pharmaceuticals USA) with that of DURICEF® 500 mg capsules (manufactured by Bristol-Myers Squibb Company)…
- Trial name
- NCT00834275
- Testing
- Cefadroxil 500 mg Capsules, DURICEF® capsules 500 mg
- Where
- 2 sites in United States, Canada
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Chronic Kidney Diseases, Magnetic Resonance Imaging
Material Balance Study of TQ-B3525
A clinical study to investigate the absorption, metabolism and excretion of [14C] TQ-B3525 in Chinese adult male healthy subjects, aiming to quantitatively analyze the total radioactivity in the excreta of male healthy subjects…
- Trial name
- NCT05675202
- Testing
- TQ-B3525
- Where
- China
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Primary IgA Nephropathy; Autoimmune Hepatitis
Relative Bioavailability Study of HR19042 in Healthy Subjects
This is a single-center, randomized, open-label, three-period, dual Latin square crossover study. Primary Objective： 1. To evaluate the oral relative bioavailability of HR19042 Capsules compared with budesonide delayed-release…
- Trial name
- NCT06922305
- Testing
- HR19042 Capsule, Tarpeyo®, Budenofalk®
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Cardiodynamics, Safety
Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects
This is a single-center, double-blind, randomized, placebo- and positive-controlled, double-dummy, parallel-group, multiple-dose, up-titration study with a nested cross-over comparison between moxifloxacin and placebo in healthy…
- Conditions
- Cardiodynamics, Safety, Tolerability, Pharmacokinetics
- Trial name
- NCT02206204
- Testing
- selexipag, moxifloxacin
- Where
- United States
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Actelion
Healthy
A Drug Interaction Study in Healthy Participants to Assess the Effect of Rifampin on the Pharmacokinetics of JNJ-42847922
The purpose of this study is to assess the effect of single- and multiple-dose of rifampin on the single-dose pharmacokinetics of JNJ-42847922 after oral administration to healthy male and female participants.
- Trial name
- NCT02661893
- Testing
- JNJ-42847922, Rifampin
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy Subjects, Depressive Disorder
GSK372475 Bioequivalence Study
The study is to show the new salt formulation of GSK372475 is equivalent to the old salt formulation of GSK372475.
- Trial name
- NCT00488098
- Testing
- GSK372475
- Where
- Canada
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
First in Man Study to Evaluate Initial Safety
Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects and Safety, Tolerability, Pharmacokinetics, and Pilot Efficacy Biomarkers in Subjects With Cold Agglutinin Disease
The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GL-0719 following single intravenous (IV) and subcutaneous injection (SC) doses in…
- Trial name
- NCT05318534
- Testing
- GL-0719
- Where
- United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Gliknik Inc.
Healthy Volunteers
Study on the Effects of DA-9701 on Gastrointestinal Motility on Healthy Adult Volunteers
DA-9701 is a new prokinetic agent formulated with Pharbitis Seed and Corydalis Tuber. These plants have been used in oriental traditional medicine for the treatment of gastrointestinal maladies.
- Trial name
- NCT01669772
- Where
- South Korea
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Myung-gui Choi
Healthy, Healthy Volunteer
Avocado and Postprandial Responses
The purpose of this study is to see how adding avocado to a breakfast meal affects blood sugar control and signals of hunger and fullness after eating.
- Conditions
- Healthy, Healthy Volunteer, Healthy Volunteers, Healthy Adult
- Trial name
- NCT06818032
- Testing
- Negative control, Avocado, Fat and fiber addition
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Vermont Medical Center
Healthy Subjects, Pharmacokinetics of ASP2205
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2205 in Healthy Young Males and Females and Elderly Females and to Evaluate the Effect of Food on the Pharmacokinetics of a Single Dose of of ASP2205
The purpose of this study is to evaluate the safety and tolerability of single ascending oral doses of ASP2205 in healthy young male and female subjects.
- Trial name
- NCT02314793
- Testing
- ASP2205
- Where
- United Kingdom
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Healthy Volunteer
Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval
The purpose of this study is to evaluate the effect of ANG-3777 on placebo-corrected change from baseline, QT/corrected QT (QTc) interval, following single intravenous (IV) doses in healthy volunteer adults.
- Trial name
- NCT04898907
- Testing
- ANG-3777 (Therapeutic Dose), ANG-3777 (Supra-therapeutic Dose), Moxifloxacin Hydrochloride
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Angion Biomedica Corp
Healthy Volunteers, Pharmacokinetics of ASP7962
A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Multiple Ascending Doses of ASP7962 in Healthy Subjects
The purpose of this study is to evaluate the safety and tolerability as well as the pharmacokinetics of increasing oral multiple doses of ASP7962 in healthy young male and female subjects.
- Trial name
- MAD (NCT02136316)
- Testing
- ASP7962
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Latrodectism
Pharmacokinetic Study Protocol of ANAWIDOW Lyophilized Powder for Solution for Intravenous Use in Fasting Conditions
A single-dose, open-label, single-treatment, single-period pharmacokinetic study under fasting conditions, in 12 healthy adult. To evaluate the single dose pharmacokinetic profile ANAWIDOW [antivenin latrodectus (black widow)…
- Trial name
- NCT04848714
- Testing
- ANAWIDOW [antivenin latrodectus (black widow) equine immune F(ab)2] lyophilized powder for solution 10 mL
- Where
- Mexico
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Healthy Volunteers, Hepatic Impairment
GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers
The primary objective of this study is to test whether mild (Child-Pugh A, score 5-6) and moderate (Child-Pugh B, score 7-9) hepatic impairment affects pharmacokinetics, safety and tolerability of GP681, compared with a control…
- Trial name
- NCT05814926
- Testing
- GP681
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.